Guna Biotherapeutics

Guna Biotherapeutics is a preclinical-stage biotechnology company focused on developing novel therapies for metabolic diseases, including obesity, type 2 diabetes, and nonalcoholic steatohepatitis (NASH). The company leverages a proprietary platform to target G-protein coupled receptors (GPCRs) with high specificity to modulate metabolic pathways. By utilizing advanced structural biology and computational modeling, Guna Biotherapeutics aims to create next-generation small molecules and peptides with improved efficacy and safety profiles compared to current standards of care. The company is currently advancing several lead candidates through early-stage development to address significant unmet needs in the global metabolic health market.